ArticleJournal of the American Chemical Society2026
Engineering a Transmembrane Receptor for Coacervate-Based Artificial Cells.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-surface receptors enable cells to sense physical or chemical stimuli and respond accordingly. Such a responsivity is key for almost all biochemical processes inside cells. Because of the importance of membrane-mediated signaling for the proper functioning of cells, mimicking this process with membrane-incorporating receptors in artificial cells is gaining interest. Here, we report on the engineering of a modular transmembrane receptor in copolymer-membrane-decorated coacervates that enables synthetic signal transduction. We have designed a heterodimerizing receptor that is dimerized via coiled-coil peptide interactions on the extracellular side upon binding to a soluble ditopic ligand. The receptor subunits are fused via a transmembrane domain to two split luciferase domains that generate bioluminescence upon receptor dimerization. The transmembrane domain is based on an elastin-like polypeptide (ELP) domain that undergoes hydrophobic interactions with the membrane-forming copolymer. Membrane insertion of the engineered proteins is dependent on the ELP sequence, and their protein diffusivity in the membrane is retained. Dose-dependent receptor activation is achieved by input ligand addition, resulting in a 5-fold increase in receptor activation. This modular system could be applied to engineer other synthetic receptors with different sensing and enzymatic output domains.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.